ArticleNature2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
Abstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 151 citations in OpenAlex.
- ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis.Blood advances · 2025Trial
- DUSP13 promotes prostate cancer progression by regulating the ERK1/2 pathway.Translational andrology and urology · 2026Article
- YBX1 regulates RNA polymerase III transcripts to prevent inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Depletion of CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Y-box-binding protein 1 stabilizes the capsid protein of porcine circovirus type 2 to promote viral replication.Virologica Sinica · 2026Article
- YBX1/PPIB axis promotes post-maturation arteriovenous fistula stenosis via enhancing endothelial to mesenchymal transition.Scientific reports · 2026Article
- Targeting the ODC1-YBX1 axis reverses gastric cancer chemoresistance via transcriptional control of SLC7A11-mediated ferroptosis.Cell death discovery · 2026Article
- Celecoxib inhibits COX-2 and initiates YAP-dependent mitochondrial apoptosis via YBX1 shuttling in hepatocellular carcinoma.Cell communication and signaling : CCS · 2026Article
- Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.British journal of haematology · 2026Article
- Airway transcriptome networks for ozone and PMGenome medicine · 2025Article
- Y-box binding proteins in immunity and RNA virus infection.Microbiology and molecular biology reviews : MMBR · 2025Review
- Histone Lactylation-Driven Upregulation of VRK1 Expression Promotes Stemness and Proliferation of Glioma Stem Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.Leukemia · 2025Article
- mCells · 2025Review
- Long non-coding RNA PRSS23-AS1 as ceRNA promotes breast cancer progression by regulating EMT via miR-3176 /YBX1 axis.Cancer gene therapy · 2025Article
- The deacetylases HDAC1/HDAC2 control JAK2Signal transduction and targeted therapy · 2025Article
- Review
- piR-RCC Suppresses Renal Cell Carcinoma Progression by Facilitating YBX-1 Cytoplasm Localization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.Nature communications · 2025Article
- Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q.Blood cancer discovery · 2025Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 14 institutions in 6 countries.
Ashok Kumar Jayavelu *Max Planck Institute of Biochemistry, Munich, Germany.
Tina M Schnöder *Innere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.
Florian PernerInnere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.
Carolin HerzogDepartment of Haematology and Oncology, Center of Internal Medicine, Otto von Guericke University Medical Center, Magdeburg, Germany.
Arno MeilerMax Planck Institute of Biochemistry, Munich, Germany.ORCID http://orcid.org/0000-0003-0012-7952
Gurumoorthy KrishnamoorthyMax Planck Institute of Biochemistry, Munich, Germany.ORCID http://orcid.org/0000-0002-7798-6707
Nicolas HuberInnere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.
Juliane MohrInnere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.
Bärbel Edelmann-StephanDepartment of Haematology and Oncology, Center of Internal Medicine, Otto von Guericke University Medical Center, Magdeburg, Germany.
Rebecca AustinQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Sabine BrandtDepartment of Nephrology and Endocrinology, Center of Internal Medicine, Otto von Guericke University Medical Center, Magdeburg, Germany.
Francesca PalandriAzienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.ORCID http://orcid.org/0000-0001-8367-5668
Nicolas SchröderPathology, Klinikum Ernst-von-Bergmann, Potsdam, Germany.
Berend IsermannInstitute for Clinical Chemistry and Pathobiochemistry, Center of Internal Medicine, Otto von Guericke University Medical Center, Magdeburg, Germany.
Frank EdlichInstitute for Biochemistry and Molecular Biology, University of Freiburg, Freiburg, Germany.
Amit U SinhaBasepair Technology Inc, New York, NY, USA.
Martin UngelenkInstitut für Humangenetik, Universitätsklinikum Jena, Jena, Germany.
Christian A HübnerInstitut für Humangenetik, Universitätsklinikum Jena, Jena, Germany.
Robert ZeiserFaculty of Biology, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0001-6565-3393
Susann RahmigLeibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany.
Claudia WaskowLeibniz Institute on Aging, Fritz Lipmann Institute, Jena, Germany.ORCID http://orcid.org/0000-0003-3261-0922
Iain ColdhamDepartment of Chemistry, University of Sheffield, Sheffield, UK.ORCID http://orcid.org/0000-0003-4602-6292
Thomas ErnstInnere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.
Andreas HochhausInnere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.
Stefanie JilgMedical Department III for Haematology and Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Philipp J JostMedical Department III for Haematology and Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.ORCID http://orcid.org/0000-0003-2454-0362
Ann MullallyDivision of Hematology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Lars BullingerClinic for Hematology, Oncology and Tumor Immunology, Charite University, Berlin, Germany.
Peter R MertensDepartment of Nephrology and Endocrinology, Center of Internal Medicine, Otto von Guericke University Medical Center, Magdeburg, Germany.
Steven W LaneQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.ORCID http://orcid.org/0000-0002-8050-6209
Matthias MannMax Planck Institute of Biochemistry, Munich, Germany. mmann@biochem.mpg.de.ORCID http://orcid.org/0000-0003-1292-4799
Florian H HeidelInnere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany. florian.heidel@uni-greifswald.de.ORCID http://orcid.org/0000-0003-2438-1955
Jena University Hospital · DEOtto-von-Guericke-Universität Magdeburg · DEMax Planck Institute of Psychiatry · DELeibniz Institute on Aging - Fritz Lipmann Institute (FLI) · DEThe University of Queensland · AUUniversitätsmedizin Greifswald · DEUniversity of Freiburg · DEAzienda USL di Bologna · ITBrigham and Women's Hospital · USCharité - Universitätsmedizin Berlin · DEKlinikum Ernst von Bergmann · DEMedical University of Graz · ATTUM Klinikum · DEUniversity of Sheffield · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
Janus kinases (JAKs) mediate responses to cytokines, hormones and growth factors in haematopoietic cells
Indexed as
AnimalsApoptosisCell LineCells, CulturedClone CellsFemaleHeterograftsHumansIntracellular Signaling Peptides and ProteinsIntronsJanus Kinase 2MaleMAP Kinase Signaling SystemMiceMutationNeoplasmsIntracellular Signaling Peptides and ProteinsJAK2 protein, humanJanus Kinase 2MKNK1 protein, humanPhosphoproteinsProtein Serine-Threonine KinasesProteomeY-Box-Binding Protein 1YBX1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.